Abstract:A series of novel fused pyrimidine derivatives are designed and synthesised, and their anticancer activity is subsequently screened against gastric adenocarcinoma cell lines using the MTT assay. A docking study was conducted and validated with CDK enzyme inhibition activity, providing robust support for the anticancer activity of this synthesised compound. Compound 4‐(2‐(pyridin‐3‐yl)‐5,6‐dihydrobenzo[h]quinazolin‐4‐yl) phenol exhibited potent anticancer activity. Our research aims to design novel pyrimidine derivatives inspired by the common pyrimidine core found in many FDA‐approved drugs. However, extensive prior research on the pyrimidine scaffold has made discovering new molecules more challenging. To overcome this obstacle, we employed a molecular hybridisation strategy, opting to hybridise tetralin and pyrimidine, recognising their potential in cancer therapeutics. The fused pyrimidine was synthesised through a base‐mediated condensation of chalcone with amidine. The reaction conditions were further optimised for base, solvent, temperature and time to produce a series of 21 novel derivatives. These compounds were subsequently screened for anticancer activity against gastric adenocarcinoma cell lines using the MTT assay. Among the synthesised compounds, 2‐(pyridin‐3‐yl)‐4‐(pyridin‐3‐yl)‐5,6‐dihydrobenzo[h]quinazoline 8b and 4‐(2‐(pyridin‐3‐yl)‐5,6 dihydrobenzo[h]quinazolin‐4‐yl) phenol 5g exhibited potent anticancer activity compared to (R)‐Roscovitine. Additionally, a molecular docking study was conducted to assess the reactivity of compound 5g, revealing that the presence of a phenolic hydroxyl group enables hydrogen bonding with CDKs and enhances anticancer activity. Furthermore, the efficacy of compound 5g was validated through an in vitro CDK2/cyclin A2 enzyme inhibition assay. Interestingly, the observed CDK2 inhibitory activity showed a good correlation with the corresponding value for the antiproliferative activity of the tested compounds.

Novel quinoline-4-carboxamide derivatives potentiates apoptosis by targeting PDK1 to overcome chemo-resistance in colorectal cancer: Theoretical and experimental results

Novel N-(3-ethynyl Phenyl)-6,7-bis(2-methoxyethoxy)Quinazoline-4-amine Derivatives: Synthesis, Characterization, Anti-cancer Activity, In-silico and DFT Studies

Design, Synthesis, Structure-Activity Relationships and Mechanism of Action of New Quinoline Derivatives As Potential Antitumor Agents

Novel 2-(5-imino-5h-isoquinolones[3,4-b]quinoxalin-7-ylmethyl)-benzonitrile (DIQ3) and Other Related Derivatives Targeting Colon Cancer Cells: Syntheses and in Vitro Models

Exploring the antitumor potential of novel quinoline derivatives via tubulin polymerization inhibition in breast cancer; design, synthesis and molecular docking

Novel Fused Pyrimidines as Potent Cyclin‐Dependent Kinases Inhibitor for Gastric Adenocarcinoma: Combined In Vitro, In Silico Anticancer Studies

Design, synthesis, graph theoretical analysis and molecular modelling studies of novel substituted quinoline analogues as promising anti-breast cancer agents

Design, synthesis, and biological evaluation of novel quinoxaline aryl ethers as anticancer agents

Design, synthesis, molecular modeling and evaluation of 2,4-diaminopyrimidine analogues as promising colorectal cancer drugs

Development of a Series of Novel 4-Anlinoquinazoline Derivatives Possessing Quinazoline Skeleton: Design, Synthesis, EGFR Kinase Inhibitory Efficacy, and Evaluation of Anticancer Activities in Vitro.

Novel quinazolines bearing 1,3,4-thiadiazole-aryl urea derivative as anticancer agents: design, synthesis, molecular docking, DFT and bioactivity evaluations

Synthesis and SAR Studies of Novel 6,7,8-Substituted 4-Substituted Benzyloxyquinolin-2(1H)-one Derivatives for Anticancer Activity.

Design and Synthesis of 6,7-Methylenedioxy-4-substituted Phenylquinolin-2(1H)-one Derivatives As Novel Anticancer Agents That Induce Apoptosis with Cell Cycle Arrest at G2/M Phase

Identification of novel quinoline analogues bearing thiazolidinones as potent kinase inhibitors for the treatment of colorectal cancer

Synthesis, antiproliferative activity, and in silico studies of quinoline-based pyrimidinedione and thiazolidinedione derivatives

Design, Synthesis and Biological Evaluation of Novel 4-Phenoxyquinoline Derivatives Containing 3-Oxo-3,4-dihydroquinoxaline Moiety As C-Met Kinase Inhibitors

Design, synthesis and anti-tumor activity evaluation of 4,6,7-substitute quinazoline derivatives

Design and synthesis of BMH-21-like quinazolinone derivatives as potential anti-cancer agents

Design and Synthesis of Some New Quinoxaline-Thiazole-Benzamide Hybrids: In Vitro Anticancer Activity and Their Molecular Docking Studies

Lead optimization of novel quinolone chalcone compounds by a structure-activity relationship (SAR) study to increase efficacy and metabolic stability

Discovery of novel 2-substituted 2, 3-dihydroquinazolin-4(1H)-one derivatives as tubulin polymerization inhibitors for anticancer therapy: The in vitro and in vivo biological evaluation